Piracetam for Treatment of Cocaine Addiction, Phase II - 4

This study has been completed.

First Received: September 20, 1999 Last Updated: November 24, 2008 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000199

Purpose

The purpose of this study is to follow patients in Phase I of an inpatient study in an eight week open label assessment of piracetam in an outpatient treatment program.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Piracetam	Phase I

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Piracetam for Treatment of Cocaine Addiction, Phase II

Resource links provided by NLM:

Drug Information available for: Piracetam

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Adverse effects
Clinical status

Estimated Enrollment:

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000199

Locations

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators

Principal Investigator:

Kyle Kampman, M.D.

University of Pennsylvania

More Information

No publications provided

Study ID Numbers:	NIDA-00238-4, K02-00238-4
Study First Received:	September 20, 1999
Last Updated:	November 24, 2008
ClinicalTrials.gov Identifier:	NCT00000199 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Nootropic Agents
Mental Disorders
Therapeutic Uses
Physiological Effects of Drugs
Substance-Related Disorders

Piracetam
Disorders of Environmental Origin
Central Nervous System Agents
Protective Agents
Neuroprotective Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 27, 2009